8 research outputs found

    Ethical challenges for the design and conduct of mega-biobanking from Great East Japan Earthquake victims

    Full text link

    Probability of relapsing in alcoholism and addiction and the Drug effect of acamprosate in relapsing patients, a meta analysis on 16 randomized controlled Trials. Opportunity of First order Markov Models in the estimates

    No full text
    Estimate of probability transition between states of Abstinence, Failure and lost to follow up. A radomized study. (Olympic Games International Novotel Hotel, February 27th 2003

    The potential exploitation of research participants in high income countries who lack access to health care

    No full text
    There are millions of individuals living in North America and the European Union who lack access to healthcare services. When these individuals participate in research, they are at increased risk of being exposed to the risks and burdens of clinical trials without realizing the benefits that result from them. The mechanisms that have been proposed to ensure that research participants in low‐ and middle‐income countries are not exploited are unlikely to protect participants in high‐income countries. The present manuscript argues that one way to address concerns about exploitation in high‐income countries would be to require sponsors to provide targeted benefits such as medical treatment during the trial, or the study drug after the trial. The latter could be achieved through extension studies, expanded access programs, or named‐patient programs. Sponsors also might provide non‐medical benefits, such as education or social support. Ethical and regulatory guidance should be revised to ensure that research participants in high‐income countries who lack access to healthcare services receive sufficient benefits
    corecore